Ensysce Biosciences Inc.

About Ensysce Biosciences Inc.

Ensysce Biosciences is a biotech company committed to stemming the prescription drug abuse epidemic by developing proprietary prodrug technologies. Their mission is to improve the care of patients with severe pain while reducing the human and economic costs associated with prescription drug abuse.

Products & Services

TAAP™:A highly novel platform that reduces the possibility of drug abuse by snorting, extracting, injection, or chewing.

Universal Application:A technology that can be applied to a large complement of oral prescription drugs.

MPAR® (Multi-Pill Abuse Resistant):A unique technology providing an additional layer of protection to reduce the possibility of drug overdose.

Specialties

Prescription Drug Abuse Prevention Pain Management Prodrug Technologies Opioid Overdose Protection

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Preferred Stock T: - FT: Convertible Preferred Stock	A: 4000000 MR: - FA: 4 million FAN: 4000000	D: 2025-11-17 FD: 2025-11-17	-
2	RT: Grant T: - FT: Grant	A: 5300000 MR: - FA: $5.3 million FAN: 5300000	D: 2025-06-04 FD: 2025-06-04	1 investors
3	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2200000 MR: - FA: $2.2 million FAN: 2200000	D: 2025-04-24 FD: 2025-04-24	1 investors
4	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 2200000 MR: - FA: approximately $2.2 million FAN: 2200000	D: 2025-04-23 FD: 2025-04-23	-
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 1100000 MR: - FA: 1.1 million FAN: 1100000	D: 2025-03-31 FD: 2025-03-31	1 investors
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-08-29 FD: 2024-08-29	-
7	RT: Grant T: - FT: Grant	A: 14000000 MR: - FA: 14 million FAN: 14000000	D: 2024-08-27 FD: 2024-08-27	2 investors
8	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 4700000 MR: - FA: 4.7 million FAN: 4700000	D: 2024-02-13 FD: 2024-02-13	-
9	RT: Convertible Note T: - FT: Convertible Note	A: 1700000 MR: - FA: $1.7 million FAN: 1700000	D: 2023-11-29 FD: 2023-11-29	1 investors
10	RT: Convertible Note T: - FT: Convertible Note	A: 1700000 MR: - FA: 1.7 million FAN: 1700000	D: 2023-10-24 FD: 2023-10-24	1 investors
11	RT: Public Offering T: - FT: Public Offering	A: 7000000 MR: - FA: approximately $7 million FAN: 7000000	D: 2023-05-12 FD: 2023-05-12	-
12	RT: Public Offering T: - FT: Public Offering	A: 7000000 MR: - FA: approximately $7 million FAN: 7000000	D: 2023-05-10 FD: 2023-05-10	-
13	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: 3.0 million FAN: 3000000	D: 2023-02-07 FD: 2023-02-07	-
14	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 3000000 MR: - FA: 3 million FAN: 3000000	D: 2023-02-03 FD: 2023-02-03	-

Convertible Preferred Stock Latest

2025-11-17

$4.0M

Grant 2025-06-04

$5.3M

Warrant Exercise 2025-04-24

$2.2M

View 13 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

D. Lynn Kirkpatrick

Chief Executive Officer

D

Dave Humphrey

Chief Financial Officer

G

Geoff Birkett

Chief Commercial Officer

L

Linda Pestano

Chief Development Officer

D

Dr. William Schmidt

Chief Medical Officer

J

Jeffrey Millard

Chief Operating Officer

View 20 more team members with Pro

Unlock Full Team Directory

Recent News